Funder: ALS Association
Due Dates (Anticipated): November 2026 (Letter of intent) | February 2027 (Invited full proposal)
Funding Amounts: Up to $1,000,000 in total costs over 2 or 3 years
Summary: Supports biomarker-driven phase 1 and phase 2a trials of ALS therapeutics and imaging tracers.
Key Information: The applicant organization must control the intellectual property, except when repurposing generic medications for ALS.
Description
The ALS Association’s Hoffman ALS Clinical Trial Awards Program supports early-stage clinical trials that translate promising laboratory science into new and improved treatments and care for people living with ALS. It funds phase 1 and phase 2a studies generating safety, dosing, and biomarker data to support later development and attract follow-on funding. Both disease-modifying and symptomatic treatments are in scope, alongside early trials of imaging tracers.
Supported approaches include small molecules, antisense oligonucleotides and other genetic therapies, stem cell approaches, peptides, and antibodies. The program is particularly interested in TDP-43 and protein aggregation. Priority goes to trials with compelling biological rationale, strong preclinical evidence, an integrated biomarker strategy, and outcomes appropriate to the trial phase.
